The total U.S. sales of media, sera, and reagents for biotechnology was $979 million in 2005 and almost $1.1 billion in 2006. At a compound annual growth rate (CAGR) of 8.9%, this market will grow to reach more than $1.6 billion in 2011.
Sera will grow much more slowly in the market. This particular sector was worth $338.5 million in 2006 and will reach $401 million by 2011, a CAGR of just 3.5%
Reagents have the greatest potential for growth, worth $382 million in 2006 and growing at a CAGR of 12.8% to reach almost $700 million by 2011.
BCC's goal in conducting this study is to provide an overview of the media, sera and reagents used in the production of cell cultures. Although this market is rising due to increased usage, the prices of media have decreased over the last few years. The main objective of this report is to determine the market size, market leaders and factors affecting the use of media, sera and reagents used in biotechnology.
The overview of media and sera-and their composition-and the use of reagents in the field of biotechnology is also examined along with sale figures over the 5-year period from 2006 to 2011. Companies selling these products are profiled, and the factors affecting markets for these products, and how those markets are likely to change, are analyzed.
Our key objective is to present a comprehensive analysis of the current market and the future direction of media, sera and reagents used in biotechnology, with an emphasis on newer products.
SCOPE OF STUDY
This report contains:
- An overview and analysis of the major types of media, sera and reagents used in biotechnology
- Global market forecasts for the industry, including current and historical data as well as 5-year market projections to 2011
- Review of the latest trends in technology, the latest important discoveries, and ideas and estimates for the future
- A detailed analysis of important patents within the past several decades
- Company profiles for the major industry players.
A comprehensive literature and patent search was conducted. The literature included technical newsletters and journals, as well as other sources. The data was collected through interviews with various pharmaceutical and biotechnology companies. Data from these first-hand and second-hand sources were compiled and the projections were based on such estimates as the current number of end-users, potential end-users, likely unit prices, rates of consumption and the market trends.
BCC surveyed many companies to obtain data for this study. Included were manufacturers and the end-users of the drug delivery systems. We gathered the data from these industries, spoke with officials of these industries, consulted newsletters, company and product literature, a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were undertaken. In addition, we compiled data from current financial and trade information and government sources.
Shalini Shahani holds a Master's degree in pharmaceutical chemistry. She has covered many research topics, including Studies on Compounds of Potential Pharmaceutical Interest, from Ibuprofen to 2-Naphthyl Acetic Acid. Shahani was awarded a Gold Medal by the prime minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC are Reagents of Chromatography, Spectroscopy: An Enduring Market; Advanced Drug Delivery Systems; Orthopedic Drugs, Implants and Devices; and Imaging Reagents.